Possible influence of some foods on the metabolism of Ibrutinib

Clinical Laboratory

Volumn 61, Issue 3-4, 2015, Pages 443-444

  Kronabel, Dieter ^a  

^a NONE   (Germany)

Author keywords

Ibrutinib; Secondary metabolites; Side effects; Toxicity

Indexed keywords

BERGAPTEN; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; FUROCOUMARIN; IBRUTINIB; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; CYTOCHROME P450 INHIBITOR; ISOENZYME; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ARTICLE; DIET SUPPLEMENTATION; DRUG METABOLISM; INTESTINE; LIVER METABOLISM; PLANT DEFENSE; STORAGE; TEA; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; FOOD; FOOD DRUG INTERACTION; HUMAN; LIVER; METABOLISM;

CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME INHIBITORS; FOOD; FOOD-DRUG INTERACTIONS; HUMANS; ISOENZYMES; LIVER; PYRAZOLES; PYRIMIDINES;

EID: 84929392567     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: 10.7754/Clin.Lab.2015.150116     Document Type: Article

References (8)

1. EMA Press release 25/07/2014. European Medicines Agency recommends approval of two new treatment options for rare cancers: Imbruvica and Zydelig to be used in different forms of blood cancers.
2. Ho PC, Saville DJ, Wanwimolruk S. Inhibition of human CVP3 A4 activity by grapefruit flavonoids, furanocoumarins and related compounds. J Pharm Pharm Sci 2001;4(3):217-27.
3. Kronabel D. [Possible influence of food on the metabolization of tyrosine kinase inhibitors]. Deutsche Zeitschrift fur Onkologie 2013;45(3):112-5.
4. Lombaert GA, Siemens KH, Pellaers P, Mankotia M, Ng W. Furanocoumarins in celery and parsnips: method and multiyear Canadian survey. J AOAC Int 2001;84(4):1135-43.
5. Manthey JA, Buslig BS. Distribution of furanocoumarins in grapefruit juice fractions. J Agric Food Chem 2005;53(13):5158-63.
6. Ostertag E, Becker T, Ammon J, Bauer-Aymanns H, Schrenk D. Effects of storage conditions on furocoumarin levels in intact, chopped, or homogenized parsnips. J Agric Food Chem 2002;50(9):2565-70.
7. Parmar S, Khilna Patel K, Pinilla-Ibarz J. Ibrutinib (Imbruvica): A Novel Targeted Therapy for Chronic Lymphocytic Leukemia. P T 2014;39(7):483-7, 519.
8. Woyach JA, Furman RR, Liu TM, et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med 2014;370(24):2286-94.